Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized Controlled Trial

Aus, Gunnar; Bergdahl, Svante; Lodding, Pär; Lilja, Hans; Hugosson, Jonas

doi:10.1016/j.eururo.2006.07.012

Cited by 109 publications

(67 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies in Gunma Prefecture and Sweden reported that mass screening could decrease the proportion of metastatic prostate cancer. 16,17 Our data are consistent with those in these previous studies and demonstrate the effectiveness of prostate cancer screening for early detection of prostate cancer. Other reports have demonstrated that PS decreased not only the rate of metastatic diseases, but also the risk of developing them during the follow-up period.…”

Section: Discussionsupporting

confidence: 82%

Prostate cancer detection by prostate-specific antigen-based screening in Japanese Hiroshima area shows early stage, low-grade, and low rate of cancer-specific death compared with clinical detection

Teishima

Maruyama

Mochizuki

et al. 2014

CUAJ

View full text Add to dashboard Cite

Introduction:We investigate the effectiveness of prostate-specific antigen (PSA) screening for prostate cancer. We compare the characteristics of 2 sets of patients: (1) those in whom prostate cancer was detected via PSA screening (the PS group) and (2) those in whom prostate cancer was detected at the outpatient office (the non-PS group). Methods: Between 2002 and 2010, prostate cancer was detected in 315 patients by PSA screening. Their age, initial PSA level, pathological findings in biopsy specimens, clinical stage, and prognosis were compared with those of 497 prostate cancer patients diagnosed at the outpatient office of the Department of Urology, Hiroshima University, in the same period. Results: The rates of patients with initial PSA higher than 50 ng/ mL, with a Gleason score of 8 or higher, and with clinical stage D were significantly lower in the PS group than those in the non-PS group. The 5-year overall survival and cancer-specific survival in the PS group was 91.3% and 98.2%, respectively; these results were significantly better than those in the non-PS group (86.4%, p = 0.0178, and 94.9%, p = 0.0112, respectively). A Cox hazard analysis showed that PSA screening was an independent predictive factor for cancer-specific survival. Conclusions: Although our study is limited by its retrospective nature and small size, the present data indicate that prostate cancer detected in the PS group showed earlier stage, lower grade, and better prognosis than in the non-PS group.

show abstract

Section: Discussionsupporting

confidence: 82%

Prostate cancer detection by prostate-specific antigen-based screening in Japanese Hiroshima area shows early stage, low-grade, and low rate of cancer-specific death compared with clinical detection

Teishima

Maruyama

Mochizuki

et al. 2014

CUAJ

View full text Add to dashboard Cite

show abstract

“…The risk of being diagnosed with metastatic PCa was reduced by 48.9% in the Swedish part of ERSPC [66]. Similar findings were reported elsewhere [67].…”

Section: Prostate Cancer Screening: Commentsupporting

confidence: 77%

Benefits and Risks of Prostate Cancer Screening

et al. 2014

View full text Add to dashboard Cite

“…The low exposure rate of PSA screening in Japan and the high exposure rate in the USA might result in completely different trends in the mortality rate as a result of prostate cancer, because although the treatment level provided in each nation might be the same, genetic and dietary factors related to the risk of developing lethal prostate cancer might be more favorable in Japanese than in Americans. 12 The publication of the ERSPC section in Sweden showed that the incidence of advanced prostate cancer cases, defined as metastatic prostate cancer and cancer with pretreatment PSA levels above 100 ng/mL, significantly decreased (49%) in the screening arm compared with the control arm 13 . The prognosis of advanced prostate cancer is worse than that of cancer detected at earlier stages.…”

Section: Review Of the Literature On Psa Screeningmentioning

confidence: 99%

Updated Japanese Urological Association Guidelines on prostate‐specific antigen‐based screening for prostate cancer in 2010

Naito¹,

Kakehi²,

Okuyama³

et al. 2010

Int J of Urology

View full text Add to dashboard Cite

Abstract:The exposure rate of screening for prostate cancer using prostate-specific antigen (PSA) in Japan is still very low compared with that in the USA or western Europe. The mortality rate of prostate cancer will increase in the future and in 2020 it will be 2.8-fold higher than in 2000. Therefore, there is an urgent need to determine the best available countermeasures to decrease the rate of prostate cancer death. PSA screening, which can reduce the risk of death as a result of prostate cancer, should be offered to all men at risk of developing prostate cancer with fact sheets showing updated benefits and drawbacks of screening for prostate cancer.Key words: prostate cancer, PSA, screening, guidelines. Policy statement of the Japanese Urological Association on screening for prostate cancerThe Japanese Urological Association (JUA) recommends prostate-specific antigen (PSA) screening, which can reduce the risk of death as a result of prostate cancer, 1 for men at risk of prostate cancer. The recommendation is based on fact sheets showing the benefits and drawbacks of screening for prostate cancer. The JUA provides the best available screening system for men who want to be screened. Theoretical background of the policy statement1 The exposure rate of screening for prostate cancer using PSA in Japan is still very low compared with that in the USA or western Europe. Therefore, many clinically significant cancer cases in Japan might be undetected and missed until they develop into clinically advanced disease.2 At present, approximately 30% of newly detected prostate cancer cases have bone metastases in municipalities where the exposure rates of populationbased PSA screening have been lower than 5%. 3 In the mean time, mortality rates as a result of prostate cancer have increased and were estimated to be 9985 in 2008. 4 The number of deaths as a result of prostate cancer will reach 21 062 in 2020.5 Therefore, there is an urgent need to determine the best available countermeasures to decrease the rate of prostate cancer death. 2 The Cancer Countermeasure Fundamental Law, which is an important national policy in Japan declared in 2007, stated the goal of a 20% decrease in the mortality rates as a result of cancer in people aged below 75 years within 10 years. The JUA recommends PSA screening, which can lead to a decrease in the mortality rate of prostate cancer, based on well-balanced fact sheets in human dry-dock (Ningen dock) and also populationbased screening for prostate cancer to contribute to achieving the goal in terms of reducing the mortality rate of prostate cancer in all age ranges. 3 The latest results from the European Randomized Study of Screening for Prostate Cancer (ERSPC) showed that the mortality rate of prostate cancer showed a 20% and 31% decrease in the screening group compared with the control group during 9 years of observation on average by intention-to-screen (ITS) analysis 1 and a second analysis adjusted by compliance and contamination for the PSA test, 6 respectively. This study clearly s...

show abstract

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized Controlled Trial

Cited by 109 publications

References 15 publications

Prostate cancer detection by prostate-specific antigen-based screening in Japanese Hiroshima area shows early stage, low-grade, and low rate of cancer-specific death compared with clinical detection

Prostate cancer detection by prostate-specific antigen-based screening in Japanese Hiroshima area shows early stage, low-grade, and low rate of cancer-specific death compared with clinical detection

Benefits and Risks of Prostate Cancer Screening

Updated Japanese Urological Association Guidelines on prostate‐specific antigen‐based screening for prostate cancer in 2010

Contact Info

Product

Resources

About